165 related articles for article (PubMed ID: 37983933)
21. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Greenacre JK; Coxon A; Petrie A; Reid JL
Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis.
Wang Y; Jiang DQ; Lu CS; Li MX; Jiang LL
Medicine (Baltimore); 2021 Nov; 100(44):e27511. PubMed ID: 34871213
[TBL] [Abstract][Full Text] [Related]
23. Istradefylline (Nourianz) for Parkinson's disease.
Med Lett Drugs Ther; 2020 Feb; 62(1591):20-23. PubMed ID: 32022788
[No Abstract] [Full Text] [Related]
24. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
25. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Yu HZ
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
[No Abstract] [Full Text] [Related]
27. Allergy to Carbidopa.
Cansino-Torres MA; Sandoval-Rodríguez V; Sáenz-Farret M; Zúñiga-Ramírez C
Clin Neuropharmacol; 2018; 41(2):75-79. PubMed ID: 29432287
[TBL] [Abstract][Full Text] [Related]
28. Current and future approaches to therapy.
Birkmayer W; Birkmayer JD
Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
[No Abstract] [Full Text] [Related]
29. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
[TBL] [Abstract][Full Text] [Related]
30. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Lees AJ
BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
[TBL] [Abstract][Full Text] [Related]
31. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
[TBL] [Abstract][Full Text] [Related]
32. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
33. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
34. [Therapy of Parkinson's disease. Practical criteria of treatment].
Casacchia M; Carolei A; Zamponi A; Agnoli A; Fazio C
Recenti Prog Med; 1976 May; 60(5):567-84. PubMed ID: 14360
[No Abstract] [Full Text] [Related]
35. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Arnold G; Kupsch A
Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
37. Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single-Center Study of 30 Patients.
Viljaharju V; Mertsalmi T; Pauls KAM; Koivu M; Eerola-Rautio J; Udd M; Pekkonen E
Mov Disord Clin Pract; 2024 Feb; 11(2):159-165. PubMed ID: 38386490
[TBL] [Abstract][Full Text] [Related]
38. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
39. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
40. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
Lyons KE; Pahwa R
Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
